Millennium Discloses 2,707,151 ALXO Shares (5.1%) on Schedule 13G

Rhea-AI Filing Summary

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 2,707,151 shares of ALX Oncology Holdings Inc. common stock, representing 5.1% of the class. The filing states the shares are held by entities subject to voting control and investment discretion of Millennium and related managers, and that the reporting persons do not claim sole ownership.

The statement is filed on a Schedule 13G, indicating a passive investment intent rather than an attempt to change control; a joint filing agreement among the three reporting persons is attached as an exhibit. The disclosure clarifies voting and disposition split as 0 shares sole power and 2,707,151 shares shared power.

Positive

• Disclosure of a 5.1% stake increases transparency for investors
• Schedule 13G classification signals the holders report a passive investment intention
• Clear breakdown of voting and dispositive power (0 sole, 2,707,151 shared) aids governance clarity

Negative

• Shared control over 2,707,151 shares could complicate predicting vote outcomes for close shareholder matters
• Potential influence on governance despite passive filing; a future switch to Schedule 13D would be material

Insights

Governance Analyst

Large passive stake disclosed with shared control implications.

The filing shows shared voting and shared dispositive power over 2,707,151 shares, equal to 5.1% of the outstanding common stock. Filing on a Schedule 13G signals an asserted passive position rather than an active effort to change company control.

Risks and dependencies include how the reporting group's voting alignment could affect close votes and proxy contests; monitor any future amendments or a move to Schedule 13D for signs of activist intent within a typical near-term horizon of a few quarters.

Equity Markets Strategist

A meaningful 5.1% holding can affect float and vote outcomes in tight situations.

Owning 2,707,151 shares gives the group a stake large enough to matter for governance votes or contested matters, but the Schedule 13G classification means the holders represent their position as non‑disruptive. The split showing 0 sole power and full shared power clarifies collective decisioning rather than individual control.

Watch for trading activity or follow‑on filings showing changes in the share count or a switch to Schedule 13D over the next several reporting periods; such changes are the concrete indicators of shifting intent.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ALX Oncology Holdings Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

00166B105

(CUSIP Number)

10/02/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 00166B105

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,707,151.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,707,151.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,707,151.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 00166B105

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,707,151.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,707,151.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,707,151.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 00166B105

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,707,151.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,707,151.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,707,151.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ALX Oncology Holdings Inc.
(b)	Address of issuer's principal executive offices: 323 Allerton Avenue, South San Francisco, California 94080
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 00166B105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	10/07/2025

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	10/07/2025

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	10/07/2025

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of October 7, 2025, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

What stake did Millennium report in ALX Oncology (ALXO)?

The reporting persons disclosed beneficial shared voting and dispositive power over 2,707,151 shares, representing 5.1% of ALXO common stock.

Does the filing indicate Millennium seeks to control ALX Oncology (ALXO)?

No. The filing was made on a Schedule 13G, which the reporting persons used to assert a passive investment intent rather than an intent to change or influence control.

How is voting and dispositive power allocated in the disclosure?

The filing reports 0 shares of sole voting/dispositive power and 2,707,151 shares of shared voting and shared dispositive power.

Who are the reporting persons named in the Schedule 13G for ALXO?

The filing lists Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander as the reporting persons.

Is there an agreement among the reporting persons?

Yes. The filing attaches a Joint Filing Agreement as an exhibit covering the reporting persons' coordination on this disclosure.